Noxopharm Ltd. · ASX:NOX
Noxopharm — IPO Roadshow (June 2016)
41 slides from Noxopharm's IPO roadshow presentation, June 2016
Slide 1: Noxopharm (ASX:NOX) Investor Presentation, June 2016
Investor Presentation, June 2016 Noxopharm (ASX:NOX) 1
Slide 2: Disclaimer
Disclaimer 4 This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscrib
Slide 3: Noxopharm focus on drug-resistance in cancer patients
Noxopharm is focused on the problem of drug-resistance in cancer patients and how it can be overturned in order that standard cytotoxic chemotherapy, the backbone of cancer therapy, can be made: • more effective • safer and • available to more patients 3
Slide 4: Idronoxil and NOX66 story
This is a story of: Idronoxil, a molecule that overturns cancer drug-resistance mechanisms & NOX66, an innovative way of delivering idronoxil designed to ensure its ability to work in humans & an objective to see NOX66 become standard of care for patients with solid cancers being treated with cytoto
Slide 5: An unwelcome truth
An unwelcome truth 1:2 men and 1:3 women will develop a life-threatening cancer 30% will die from that cancer within 5 years 5
Slide 6: Cancer Therapy Options
Cancer Therapy Options Frontline / First Line Therapies Second Line Therapies Immunotherapies Surgery Hormone Therapies Therapies that damage/ kill cells Cytotoxic Anti-angiogenics (cytotoxic therapy) chemotherapy remain the backbone of cancer therapy Gene silencing/anti-sense Radiotherapy Targeted
Slide 7: After 45 Years of Cytotoxic Chemotherapy
After 45 Years of Cytotoxic Chemotherapy... • Pancreas Little or no • Lung progress • Brain made in • Head and neck survival • Oesophagus outcome for • Stomach cancers of: • Cervix • Bladder BUT….even where progress has been made, many cancers eventually recur and ultimately become resistant to chem
Slide 8: Drug-Resistance: major obstacle to successful chemotherapy
Drug-Resistance: major obstacle to successful chemotherapy Pre-treatment Response Recurrence Primary resistance: Resistant to first-line Rx (pancreatic cancer, melanoma) Acquired resistance: Respond to first-line Rx, then develop resistance 8
Slide 9: Drug-Resistance: multiple mechanisms
Drug-Resistance: multiple mechanisms 1 Pumps drug out Downgrades target 6 importance 2 Blocks drug entry 5 Amplifies target 3 Destroy drug 4 Increases DNA repair 9
Slide 10: Drug-Resistance: #1
Drug-Resistance: #1 Drug cannot reach Drug enters cell its target but is pumped out by efflux pump 10
Slide 11: Drug-Resistance: #2
Drug-Resistance: #2 Drug blocked from entering cell 11
Slide 12: Drug-Resistance: #3
Drug-Resistance: #3 Drug enters cell but x is destroyed before it x can act x 12
Slide 13: Drug-Resistance: #4
Drug-Resistance: #4 Drug inflicts damage but cell up-regulates repair mechanisms 13
Slide 14: Drug-Resistance: #5
Drug-Resistance: #5 Cell amplifies target: drug loses effectiveness 14
Slide 15: Drug-Resistance: #6
Drug-Resistance: #6 Cell downgrades importance of target: uses alternative pathway 15
Slide 16: Why drug-resistance to cytotoxic drugs is hard to over-ride
Why drug-resistance to cytotoxic drugs is hard to over-ride Poison action: Cytotoxic drugs work by damaging the cell Action is non-selective: Also damage healthy cells (bone marrow, hair follicles, gut lining, nerves) Drug dosage that might kill Current dosage levels most cancer cells Restriction: T
Slide 17: Noxopharm Aim
Noxopharm Aim Improved response rates in most forms of solid cancers To overturn drug-resistance Allow drug dose rates to be lowered to reduce toxicity to the most commonly- Permit chemotherapy in used elderly/frail patients chemotherapies Provide safer chemotherapy in children 17
Slide 18: Chemotherapy Dosage/Toxicity
Chemotherapy Dosage/Toxicity Toxic dosage Current dosage Optimum dosage 100% cancer cell kill. <100% cancer cell kill. 100% cancer cell kill. Lethal toxicity to patient. Tolerable toxicity. Little or no toxicity. NOX66 is intended to achieve this 18
Slide 19: Noxopharm: The Company
Noxopharm: The Company _ J& NOXOPHARM
Slide 20: Experienced Team
Experienced Team Graham Kelly PhD Dr Ian Dixon PhD, MBA Managing Director Non-Executive Director •Head of research team at University of Sydney that discovered idronoxil in 1992 •Over 20 years’ experience in the biotechnology and medical device industries and •Founded (CEO) Novogen Ltd (ASX 1994; NA
Slide 21: Investment Highlights
Investment Highlights • Chemo-sensitisation. Making standard cytotoxic Pharmaceutical field chemotherapies more effective by overcoming drug-resistance • Bring NOX66 to market to improve response to current Objective standard of care drugs plus reduce side-effects Market Size • Most patients with li
Slide 22: The Science
fj. ~ E es. The Science = ( } _ J& NOXOPHARM
Slide 23: Idronoxil History
Idronoxil History Idronoxil Discovered in 1992 Basis of formation of Novogen Ltd Potent sensitiser of standard cytotoxic anti- History (ASX:1994). cancer drugs in test- tube and animals Phase III study chemo- Evidence of anti-cancer sensitising effect (+ (monotherapy) and Entered clinical carboplati
Slide 24: Pro-life Pro-death
H+ H+ H+ H+ H+ H+ ENOX H+ PROTON PUMP Pro-life Pro-death H+ NADH DRUG-RESISTANCE H + reductase 24
Slide 25: Idronoxil action on ENOX
idronoxil ❌ ENOX H+ ❌ ❌ Pro-death H+ + PROTON PUMP H+ H+ Pro-life H H+ + H+ H H+ H+ NADH DRUG-RESISTANCE H + reductase H+ H+ 25
Slide 26: Noxopharm rebirth idronoxil
Noxopharm rebirth idronoxil Noxopharm has re-birthed idronoxil because • We consider it remains the most potent INHIBITOR of cancer drug resistance mechanisms yet developed • It overturns resistance to the most commonly-used We believe we know chemotherapies in oncology why idronoxil failed • It wor
Slide 27: The Problem: Phase 2 Metabolism
The Problem: Phase 2 Metabolism Body attaches sugar to idronoxil: blocks access to target idronoxil glucuronic acid NOX66: innovative formulation designed to prevent Phase 2 metabolism 27
Slide 28: Clinical Program
Clinical Program _ I NOXOPHARM
Slide 29: NOX66: Potential Clinical Indications
NOX66: Potential Clinical Indications • Cisplatin • Carboplatin Overcome a cancer cell’s resistance to: • Paclitaxel • Docetaxel • Gemcitabine • Doxorubicin • Topotecan Primary Resistance • Improve response rates where first-line treatments currently poorly effective (eg. pancreatic cancer, lung can
Slide 30: NOX66: Phase 1a/1b Clinical Study
NOX66: Phase 1a/1b Clinical Study Number of sites 2 (planned recruitment, 1.5 patient per site per month Territory Eastern Europe Commence Q4 2016 Patients Solid Tumours • that have failed to respond to standard therapies, or • where the patient has elected not to receive therapy, or • where the pat
Slide 31: NOX66: Potential Phase 2a Study
NOX66: Potential Phase 2a Study Adaptive design • Phase 2a Study triggered by meaningful clinical responses (complete or partial remission) in Phase 1b Study • Immediate recruitment • 2 additional cohorts; 10 patients per cohort • 2 specific tumour types • 6 treatment cycles of NOX66 + carboplatin P
Slide 32: Proposed clinical study timeline
Proposed clinical study timeline 3Q 2016 4Q 2016 1Q 2017 2Q 2017 3Q 2017 4Q 2017 Study start Complete Phase 1a Complete Phase 1b (Low Dose) Complete Phase 1b (High Dose) 32
Slide 33: The Offer
The Offer _ J& NOXOPHARM
Slide 34: Key Offer Statistics
Key Offer Statistics Cap structure Offer details Existing NOX Shares 45,172,429 Offer price per Share A$0.20 New Shares Offered 30,000,000 Cash proceeds from Offer A$6.0M Total Shares at re-listing 75,171,429 Options* 22,500,000 Performance Shares** 10,000,000 * Exercise price = $0.30; expiry Feb 20
Slide 35: Use of Proceeds
Use of Proceeds AUD$6 million Phase 1b Clinical Research & Cost of Offer Working Capital Study Development Develop core • Administration Phase 1a/1b/2a technology for 2nd • Working capital generation drugs $0.51M $2.50M $0.55M $2.80M* * Includes $0.37M pre-IPO cash 35
Slide 36: Key Investment Risks
Key Investment Risks Clinical Trials Clinical trials may prove unsuccessful Intellectual Property Key patents may not be granted, allowing others players to enter the same market Others may claim infringement of existing IP Competition Other drugs unknown to the Company and with similar or greater b
Slide 37: Concluding Remarks
Concluding Remarks _ J& NOXOPHARM
Slide 38: Major Opportunity
Major Opportunity Drug-resistance major block to more successful cancer therapy Noxopharm believes idronoxil is the most potent reverser of drug-resistance Delivering idronoxil to humans in a form that works has proved challenging Noxopharm believes it has solved the problem…NOX66... an innovative m
Slide 39: Value Drivers
Value Drivers Large Lack of Clinic- Expeditious market size competition Experience ready clinical plan No current drug Over 20 years’ Substantial or known drug Indication of in development experience with Phase 1 study unmet need for this technology efficacy most patients with same to commence in po
Slide 40: Key Messages
Key Messages Resistance to cytotoxic chemotherapy remains the most pressing and largest problem facing patients No drug has come to market that successfully treats this problem Idronoxil holds that promise but faltered at the final hurdle Noxopharm is confident it knows why it faltered and is confid
Slide 41: Contact
Contact Dr Graham Kelly Chief Executive Officer [email protected] 41